When should maintenance carbimazole be discontinued in a patient with Graves disease who is euthyroid, with thyroid‑stimulating hormone values <0.01–0.02 up to 0.04 and free T4 approximately 18 pmol/L?

When to Stop Maintenance Carbimazole in Your Patient

You should discontinue carbimazole after 12-18 months of treatment if TSH has normalized, but your patient's TSH of 0.04 mU/L (while improved) is still not fully normal—continue treatment until TSH is consistently normal, then taper or discontinue. 1

Critical Assessment of Your Patient's Status

Your patient shows incomplete biochemical remission:

• TSH progression: <0.01 → 0.02 → 0.04 mU/L (improving but still suppressed; normal is typically 0.4-4.0 mU/L)
• Free T4: 18 pmol/L (appears normal, assuming reference range ~12-22 pmol/L)
• Clinical status: Euthyroid

The key issue: TSH remains below normal despite normal T4. This represents subclinical hyperthyroidism and indicates ongoing thyroid autonomy.

Evidence-Based Discontinuation Criteria

Primary Guideline Recommendations

The American Thyroid Association/American Association of Clinical Endocrinologists guidelines explicitly state: "medication should be continued for approximately 12-18 months, then tapered or discontinued if the TSH is normal at that time." 1

The 2018 European guidelines reinforce this, emphasizing that TSH may remain below normal for several weeks after normalization of thyroid function 2, but discontinuation should occur only after TSH normalization.

Why TSH Normalization Matters

Research demonstrates that suppressed TSH predicts higher relapse risk. A study of 84 patients in clinical remission found that those with suppressed TSH (<0.10 mU/L) had significantly higher relapse rates (P<0.02), even when T4 and T3 were normal 3. This represents subclinical hyperthyroidism with increased relapse risk.

Your Management Algorithm

Step 1: Continue Current Therapy

• Do not stop carbimazole yet—TSH is not normalized
• Maintain current low-dose carbimazole (likely 5-10 mg daily based on standard maintenance dosing)
• Monitor TSH and free T4 every 2 months 2

Step 2: Assess Treatment Duration

• Calculate total treatment duration from initiation
• If approaching or exceeding 18 months with persistent TSH suppression, consider alternative strategies

Step 3: Check TRAb Before Discontinuation

Measure TSH receptor antibodies (TRAb) when considering stopping therapy 1. This aids in predicting remission:

• Normal TRAb = greater chance for remission
• Positive TRAb = higher relapse risk

Step 4: Discontinuation Criteria (All Must Be Met)

1. TSH normalized (≥0.4 mU/L, not just 0.04)
2. Free T4 remains normal
3. Treatment duration 12-18 months minimum
4. Preferably TRAb negative (though not absolute requirement)

Step 5: Post-Discontinuation Monitoring

After stopping carbimazole 2:

• Check thyroid function at 3-4 weeks
• Then every 3 months for 1 year
• Patient considered in remission if thyroid function remains normal for 1 year
• Continue annual monitoring thereafter (5-20% may develop hypothyroidism spontaneously)

Common Pitfalls to Avoid

Don't confuse clinical euthyroidism with biochemical remission: Your patient feels well but TSH remains suppressed—this is subclinical hyperthyroidism, not true remission.

Don't rely solely on T4 levels: The guidelines specifically require normal TSH, not just normal T4 1. TSH is the more sensitive marker for complete remission.

Don't stop prematurely: Stopping at 0.04 mU/L TSH increases relapse risk. Wait for full normalization (≥0.4 mU/L).

Alternative Considerations

If TSH fails to normalize after 18 months of treatment:

1. Consider definitive therapy (radioactive iodine or thyroidectomy) 1
2. Long-term low-dose carbimazole is acceptable if patient refuses definitive treatment 1
3. Reassess diagnosis: Ensure this is truly Graves' disease and not toxic nodular goiter

Bottom Line for Your Patient

Continue carbimazole until TSH normalizes to ≥0.4 mU/L. The current TSH of 0.04 mU/L, while improved, does not meet discontinuation criteria. Check TRAb levels now to help predict remission likelihood. If TSH normalizes and TRAb is negative, you can safely discontinue after completing 12-18 months total treatment duration. If TSH remains suppressed beyond 18 months, discuss definitive therapy options.